Major changes have occurred in therapeutics for coronavirus-19 (COVID-19) infection over
the past 12–18 mo, most notably in early outpatient therapy. In most cases, solid organ …

The SARS-CoV-2 pandemic continues to place a substantial burden on healthcare systems.
Outpatient therapies for mild-to-moderate disease have reduced hospitalizations and deaths …

The Omicron variant, which has become the dominant strain of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) worldwide, brings new challenges to preventing and …

Background Solid organ transplant recipients (SOTRs) are at high‐risk for severe infection
from severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Anti‐spike …

Introduction: Existing studies report variable impact of vaccination on Coronavirus Disease
(COVID-19) morbidity and mortality in solid organ transplant (SOT) recipients. This study …

Rationale & Objective Neutralizing monoclonal antibody treatments have shown promising
preliminary results in kidney transplant recipients infected with severe acute respiratory …

At the start of the pandemic, liver transplant recipients (LTR) were at high risk of developing
severe COVID-19. Here, the outcomes of breakthrough infections in fully vaccinated LTR (n …

Vulnerable patients such as immunosuppressed or elderly patients are at high risk for a
severe course of COVID-19 upon SARS-CoV-2 infection. Immunotherapy with SARS-CoV-2 …

According to the WHO, more than 30 million children under five years of age still suffer from
vaccine-preventable diseases (VPDs) every year in Africa. 1 Of these, over half a million die …

Background Sotrovimab is a neutralizing monoclonal antibody (mAb) that seems to remain
active against recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …